Serum level of apelin-13 negatively correlated with NT-proBNP in heart failure patients

1. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3(3):315-22. DOI: 10.1016/S1388-9842(00)00141-0.10.1016/S1388-9842(00)00141-0Search in Google Scholar

2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46. DOI: 10.1136/hrt.2003.025270.10.1136/hrt.2003.025270195504017699180Search in Google Scholar

3. Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, et al. Relationship between early physician follow-up and 30-day read-mission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303(17):1716-22. DOI: 10.1001/jama.2010.533.10.1001/jama.2010.53320442387Search in Google Scholar

4. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30-41. DOI: 10.1038/nrcardio.2010.165.10.1038/nrcardio.2010.165303349621060326Search in Google Scholar

5. Aalbers J. New ESC heart failure guidelines with South African expert comment. Cardiovasc J Afr. 2012;23(5):295-6.Search in Google Scholar

6. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646-59. DOI: 10.1161/CIRCRESAHA.113.300268.10.1161/CIRCRESAHA.113.300268380629023989710Search in Google Scholar

7. Goidescu CM, Vida-Simiti LA. The Apelin-APJ System in the Evolution of Heart Failure. Clujul Med. 2015;88(1):3-8. DOI: 10.15386/cjmed-380.10.15386/cjmed-380450860926528040Search in Google Scholar

8. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc. 2008;40(10):3466-9. DOI: 10.1016/j.transproceed.2008.03.163.10.1016/j.transproceed.2008.03.16319100415Search in Google Scholar

9. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci. 2008;53(1):32-6. DOI: 10.2478/v10039-008-0024-x.10.2478/v10039-008-0024-x18635422Search in Google Scholar

10. Vida-Simiti L, Todor I, Stoia M, Gherman C, Goidescu C. Plasma levels of resistin predicts cardiovascular events. RRML. 2014;22(1):35-47. DOI: 10.2478/rrlm-2014-0011.10.2478/rrlm-2014-0011Search in Google Scholar

11. Vida-Simiti LA, Todor I, Stoia MA, Goidescu CM, Anton FP, Farcas AD. Better prognosis in overweight/obese coronary heart disease patients with high plasma levels of leptin. Clujul Med. 2016;89(1):65-71. DOI: 10.15386/cjmed-524.10.15386/cjmed-524477747127004027Search in Google Scholar

12. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91(5):434-40. DOI: 10.1161/01.RES.0000033522.37861.69.10.1161/01.RES.0000033522.37861.69Search in Google Scholar

13. Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun. 2003;308(3):480-5. DOI: 10.1016/S0006-291X(03)01424-4.10.1016/S0006-291X(03)01424-4Search in Google Scholar

14. Emam MN, Abo El gheit RE. Promoting effect of adipocytokine, apelin, on hepatic injury in caerulein-induced acute pancreatitis in rats: Apelin on AP-induced hepatic injury. Alexandria Journal of Medicine. DOI: 10.1016/j.ajme.2015.11.003. DOI: 10.1016/j.ajme.2015.11.003.10.1016/j.ajme.2015.11.003Search in Google Scholar

15. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8(4):355-60. DOI: 10.1016/j.ejheart.2005.10.007.10.1016/j.ejheart.2005.10.00716464638Search in Google Scholar

16. Zhang J, Ren CX, Qi YF, Lou LX, Chen L, Zhang LK, et al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci. 2006;79(12):1153-9. DOI: 10.1016/j.lfs.2006.03.040.10.1016/j.lfs.2006.03.04016674982Search in Google Scholar

17. Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J. 2012;76(1):137-44. DOI: 10.1253/circj.CJ-11-0689.10.1253/circj.CJ-11-068922082814Search in Google Scholar

18. Soliman M, Arafah M. Apelin protect against multiple organ injury following hemorrhagic shock and decrease the inflammatory response. Int J Appl Basic Med Res. 2015;5(3):195-9. DOI: 10.4103/2229-516X.165377.10.4103/2229-516X.165377460658026539370Search in Google Scholar

19. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204(1):222-8. DOI: 10.1016/j.atherosclerosis.2008.08.030.10.1016/j.atherosclerosis.2008.08.03018845302Search in Google Scholar

20. Heinonen MV, Laaksonen DE, Karhu T, Karhunen L, Laitinen T, Kainulainen S, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2009;19(9):626-33. DOI: 10.1016/j.numecd.2008.12.008.10.1016/j.numecd.2008.12.00819278844Search in Google Scholar

21. Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Calixto A, Geloneze B, et al. Apelin: a peptide involved in cardiovascular risk in hemodialysis patients? Ren Fail. 2012;34(5):577-81. DOI: 10.3109/0886022X.2012.668490.10.3109/0886022X.2012.66849022417287Search in Google Scholar

22. Wang M, Gupta RC, Rastogi S, Kohli S, Sabbah MS, Zhang K, et al. Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Card Fail. 2013;19(7):509-16. DOI: 10.1016/j.cardfail.2013.05.004.10.1016/j.cardfail.2013.05.004370699523834927Search in Google Scholar

23. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006;553(1-3):222-8. DOI: 10.1016/j.ejphar.2006.09.034.10.1016/j.ejphar.2006.09.034181530117055480Search in Google Scholar

24. Jia ZQ, Hou L, Leger A, Wu I, Kudej AB, Stefano J, et al. Cardiovascular effects of a PEGylated apelin. Peptides. 2012;38(1):181-8. DOI: 10.1016/j.peptides.2012.09.003.10.1016/j.peptides.2012.09.00322986020Search in Google Scholar

25. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121(16):1818-27. DOI: 10.1161/CIRCULATIONAHA.109.911339.10.1161/CIRCULATIONAHA.109.91133920385929Search in Google Scholar

26. Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013;6(3):482-91. DOI: 10.1161/CIRCHEARTFAILURE.111.000077.10.1161/CIRCHEARTFAILURE.111.00007723519586Search in Google Scholar

27. Masri B, Knibiehler B, Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal. 2005;17(4):415-26. DOI: 10.1016/j.cell-sig.2004.09.018.Search in Google Scholar

28. Masri B, Morin N, Pedebernade L, Knibiehler B, Audigier Y. The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem. 2006;281(27):18317-26. DOI: 10.1074/jbc.M600606200.10.1074/jbc.M60060620016679320Search in Google Scholar

29. Zhen EY, Higgs RE, Gutierrez JA. Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. Anal Biochem. 2013;442(1):1-9. DOI: 10.1016/j.ab.2013.07.006.10.1016/j.ab.2013.07.00623872001Search in Google Scholar

30. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1] apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009;54(3):598-604. DOI: 10.1161/HYPERTENSIONAHA.109.134619.10.1161/HYPERTENSIONAHA.109.13461919597036Search in Google Scholar

31. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803-69. DOI: 10.1093/eurjhf/hfs105.10.1093/eurjhf/hfs10522828712Search in Google Scholar

32. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14.10.1016/j.echo.2014.10.00325559473Search in Google Scholar

33. Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovasc Ultrasound. 2005;3:17. DOI: 10.1186/1476-7120-3-17.10.1186/1476-7120-3-17118323015963236Search in Google Scholar

34. Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JA. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging. 2012;5(8):837-48. DOI: 10.1016/j.jcmg.2012.06.003.10.1016/j.jcmg.2012.06.003350120922897998Search in Google Scholar

35. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2015. Available from: http://www.r-project.org/.Search in Google Scholar

36. Miettinen KH, Magga J, Vuolteenaho O, Vanninen EJ, Punnonen KR, Ylitalo K, et al. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept. 2007;140(3):178-84. DOI: 10.1016/j.regpep.2006.12.004.10.1016/j.regpep.2006.12.00417223209Search in Google Scholar

37. Pitkin SL, Maguire JJ, Kuc RE, Davenport AP. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol. 2010;160(7):1785-95. DOI: 10.1111/j.1476-5381.2010.00821.x.10.1111/j.1476-5381.2010.00821.x293684920649580Search in Google Scholar

38. Liu HT, Chen M, Yu J, Li WJ, Tao L, Li Y, et al. Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention. Medicine (Baltimore). 2015;94(4):e449. DOI: 10.1097/MD.0000000000000449.10.1097/MD.0000000000000449460295325634182Search in Google Scholar

39. Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S, et al. Apelin: a novel marker for the patients with first ST-elevation myocar-dial infarction. Heart Vessels. 2010;25(5):363-7. DOI: 10.1007/s00380-009-1217-3.10.1007/s00380-009-1217-320676956Search in Google Scholar

40. Chandrasekaran B, Kalra PR, Donovan J, Hooper J, Clague JR, McDonagh TA. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Card Fail. 2010;16(7):556-61. DOI: 10.1016/j.cardfail.2010.02.004.10.1016/j.cardfail.2010.02.00420610231Search in Google Scholar